Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-01-18
2010-10-12
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100, C424S205100, C435S235100, C435S236000
Reexamination Certificate
active
07811582
ABSTRACT:
An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus.
REFERENCES:
patent: 5998174 (1999-12-01), Glorioso et al.
patent: 6641817 (2003-11-01), Coffin
patent: 6713067 (2004-03-01), Coffin
patent: WO 97/13866 (1997-04-01), None
patent: WO 98/04726 (1998-02-01), None
patent: WO 98/30707 (1998-07-01), None
patent: WO 98/51809 (1998-11-01), None
patent: WO 99/60145 (1999-11-01), None
patent: WO 00/08191 (2000-02-01), None
Krisky et al. Development of herpes simplex virus replication defective multigene vectors for combination gene therapy applications. Gene Therapy, Nov. 1998, vol. 5, No. 11, pp. 1517-1530.
Coffin et al. Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry. Gene Therapy, May 1998, vol. 5, No. 5, pp. 718-722.
Ace et al. “Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression” J. Virol. 63:2260-2269 (1989).
Aicher et al. “Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells” Exp. Hematol. 25:39-44 (1997).
Arthur et al. “A comparison of gene transfer methods in human dendritic cells” Cancer Gene Therapy 4:17-25 (1997).
Caux et al. “GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells” Nature 360:258-261 (1992).
Celluzzi et al. “Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity” J. Exp. Med. 183:283-287 (1996).
Chou et al. “Differential response of human cells to deletions and stop codons in theγ134.5 gene of herpes simplex virus” J. Virol. 68:8304-8311 (1994).
Chou et al. “Theγ134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristics of programmed cell death in neuronal cells” Proc. Natl. Acad. Sci. USA 89:3266-3270 (1992).
Coffin et al. “Herpes simplex virus-based vectors” inGene Manipulation of the Nervous System(Latchman, ed.), Academic Press, Chapter 6, pp. 100-114 (1995).
Coffin et al. “Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors” Gene Therapy 3:886-891 (1996).
Coffin et al. “Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry” Gene Therapy 5:718-722 (1998).
DeLuca et al. “Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4” J. Virol. 56:558-570 1985.
Dilloo et al. “A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells” Blood 89:119-127 (1997).
Geiss et al. “Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain” J. Virol. 74:111137-11144 (2000).
Gendler et al. “Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin” J. Biol. Chem. 265:15286-15293 (1990).
Girolomoni et al. “Dendritic cells hold promise for immunotherapy” Immunology Today 18:103-104 (1997).
Goldsmith et al. “Infected Cell Protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8 T cell response” J. Exp. Med. 187:341-348 (1998).
Gossen et al. “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters” Proc. Natl. Acad. Sci. USA 89:5547-5551 (1992).
Gough et al. “Expression of the hepatitis B virus surface, core and E antigen genes by stable rat and mouse cell lines” J. Mol. Biol. 162:43-67 (1982).
Huard et al. “Gene transfer to muscle using herpes simplex virus-based vectors” Neuromuscular Disorders 7:299-313 (1997) (Abstract only cited).
Inaba et al. “Identification of proliferating dendritic cell precursors in mouse blood” J. Exp. Med. 175:1157-1167 (1992).
Jones et al. “Mutational analysis of the herpes simplex virus virion host shutoff protein: Evidence that vhs functions in the absence of other viral proteins” J. Virol. 69:4863-4871 (1995).
Krisky et al. “Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications” Gene Therapy 5:1517-1530 (1998).
Kruse et al. “Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity” J. Virol. 74:7127-7136 (2000).
Lokensgard et al. “Long-term promoter activity during herpes simplex virus latency” J. Virol. 68:7148-7158 (1994).
MacLean et al. “Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17 between immediate early gene 1 and the ‘a’ sequence” J. Gen. Virol. 72:631-639 (1991).
MacLean et al. “Investigation of herpes simplex virus type 1 genes encoding multiply inserted membrane proteins” J. Gen. Virol. 72:897-906 (1991).
McFarlane et al. “Hexamethylene bisacetamide stimulates herpes simplex virus immediate early gene expression in the absence of trans-induction by Vmw65” J. Gen. Virol. 73:285-292 (1992).
Reeves et al. “Retroviral transduction of human dendritic cells with a tumor-associated antigen gene” Cancer Research 56:5672-5677 (1996).
Rice et al. “Genetic evidence for two distinct transactivation functions of the herpes simplex virus α protein ICP27” J. Virol. 64:1704-1715 (1990).
Salio et al. “Inhibition of dendritic cell maturation by herpes simplex virus” Eur. J. Immunol. 29:3245-3253 (1999).
Sallusto et al. “Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α” J. Exp. Med. 179:1109-1118 (1994).
Samaniego et al. “Functional interactions between herpes simplex virus immediate-early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4” J. Virol. 69:5705-5715 (1995).
Smiley et al. “Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 produces a phenotype similar to that of thein1814 linker insertion mutation” J. Virol. 71:6191-6193 (1997).
Smith et al. “Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression” Virology 186:74-66 (1992).
Strelow et al. “Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis” J. Virol. 69:6779-6786 (1995).
Thomas et al. “Herpes simplex virus latency-associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency” J. Virol. 73:6618-6625 (1999).
Thompson et al. “Herpes simplex virus neurovirulence and productive infection of neural cells is associated with a function which maps between 0.82 and 0.832 map units on the HSV genome” Virology 172:435-450 (1989).
Wagstaff et al. “Gene transfer using a disabled herpes virus vector containing the EMCV IRES allows multiple gene expression in vitro and in vivo” GeneTherapy 5:1566-1570 (1998).
Walker et al. “Protection from primary infection and establishment of laten
Biovex Limited
Lucas Zachariah
Nixon & Vanderhye P.C.
LandOfFree
Herpes viruses for immune modulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes viruses for immune modulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes viruses for immune modulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240353